Crossref
PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT
Duhok Medical Journal · 2018
DOI: 10.31386/dmj.2017.11.5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Duhok Medical Journal, 2018. Verfasst von TWANA TAHER QADER und 2 weiteren Autor:innen.
Themen: Intensivpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
QADER, T. T., ABDULMAJEED, O. I., & ZANGANA, A. M. (2018). PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT. Duhok Medical Journal. https://doi.org/10.31386/dmj.2017.11.5
Vancouver
QADER TT, ABDULMAJEED OI, ZANGANA AM. PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT. Duhok Medical Journal. 2018. doi:10.31386/dmj.2017.11.5
BibTeX
@article{QADER2018,
author = {QADER, TWANA TAHER and ABDULMAJEED, OTHMAN ISMAT and ZANGANA, ABDULQADIR M.},
title = {PROPOFOL - REMIFENTANIL VERSUS MIDAZOLAM - FENTANYL IN CORONARY ARTERY BYPASS GRAFT SURGERY AND INTENSIVE CARE UNIT},
journal = {Duhok Medical Journal},
year = {2018},
doi = {10.31386/dmj.2017.11.5}
}
EUVIMED